JP2020512917A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512917A5 JP2020512917A5 JP2020502533A JP2020502533A JP2020512917A5 JP 2020512917 A5 JP2020512917 A5 JP 2020512917A5 JP 2020502533 A JP2020502533 A JP 2020502533A JP 2020502533 A JP2020502533 A JP 2020502533A JP 2020512917 A5 JP2020512917 A5 JP 2020512917A5
- Authority
- JP
- Japan
- Prior art keywords
- eye
- exemplary
- laser
- tissue
- present disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001508 eye Anatomy 0.000 description 314
- 210000001519 tissue Anatomy 0.000 description 252
- 238000000034 method Methods 0.000 description 226
- 239000011148 porous material Substances 0.000 description 192
- 238000011282 treatment Methods 0.000 description 153
- 210000000695 crystalline len Anatomy 0.000 description 151
- 210000003786 sclera Anatomy 0.000 description 151
- 230000001886 ciliary effect Effects 0.000 description 73
- 239000011159 matrix material Substances 0.000 description 65
- 210000004087 cornea Anatomy 0.000 description 64
- 210000003205 muscle Anatomy 0.000 description 64
- 238000002679 ablation Methods 0.000 description 57
- 210000002808 connective tissue Anatomy 0.000 description 56
- 239000010410 layer Substances 0.000 description 55
- 230000003287 optical effect Effects 0.000 description 53
- 230000000694 effects Effects 0.000 description 52
- 230000006870 function Effects 0.000 description 52
- 238000012384 transportation and delivery Methods 0.000 description 51
- 229910001868 water Inorganic materials 0.000 description 51
- 239000000835 fiber Substances 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 238000004088 simulation Methods 0.000 description 46
- 238000010521 absorption reaction Methods 0.000 description 45
- 239000003814 drug Substances 0.000 description 45
- 230000004308 accommodation Effects 0.000 description 43
- 229940079593 drug Drugs 0.000 description 43
- 239000000463 material Substances 0.000 description 41
- 238000001356 surgical procedure Methods 0.000 description 41
- 102000008186 Collagen Human genes 0.000 description 35
- 108010035532 Collagen Proteins 0.000 description 35
- 229920001436 collagen Polymers 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 34
- 230000035882 stress Effects 0.000 description 34
- 230000008569 process Effects 0.000 description 32
- 230000008901 benefit Effects 0.000 description 31
- 230000004410 intraocular pressure Effects 0.000 description 31
- 230000008859 change Effects 0.000 description 30
- 238000013461 design Methods 0.000 description 30
- 238000004422 calculation algorithm Methods 0.000 description 28
- 238000010586 diagram Methods 0.000 description 28
- 238000012014 optical coherence tomography Methods 0.000 description 28
- 210000003484 anatomy Anatomy 0.000 description 27
- 230000001965 increasing effect Effects 0.000 description 27
- 230000033001 locomotion Effects 0.000 description 27
- 238000005259 measurement Methods 0.000 description 26
- 210000001742 aqueous humor Anatomy 0.000 description 25
- 238000013532 laser treatment Methods 0.000 description 25
- 238000013507 mapping Methods 0.000 description 25
- 230000003716 rejuvenation Effects 0.000 description 25
- 230000032683 aging Effects 0.000 description 24
- 238000012377 drug delivery Methods 0.000 description 24
- 238000003384 imaging method Methods 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 24
- 230000004044 response Effects 0.000 description 23
- 230000001105 regulatory effect Effects 0.000 description 22
- 229910019655 synthetic inorganic crystalline material Inorganic materials 0.000 description 21
- 230000033228 biological regulation Effects 0.000 description 20
- 230000007246 mechanism Effects 0.000 description 20
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 19
- 229920002683 Glycosaminoglycan Polymers 0.000 description 19
- 241000764238 Isis Species 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 210000003161 choroid Anatomy 0.000 description 19
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 19
- 238000012739 integrated shape imaging system Methods 0.000 description 19
- 230000002350 accommodative effect Effects 0.000 description 18
- 238000012544 monitoring process Methods 0.000 description 18
- 230000000007 visual effect Effects 0.000 description 18
- 201000010041 presbyopia Diseases 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 239000012530 fluid Substances 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 16
- 210000000056 organ Anatomy 0.000 description 16
- 238000012800 visualization Methods 0.000 description 16
- 210000004204 blood vessel Anatomy 0.000 description 15
- 210000000744 eyelid Anatomy 0.000 description 15
- 230000001788 irregular Effects 0.000 description 15
- 230000001976 improved effect Effects 0.000 description 14
- 238000003032 molecular docking Methods 0.000 description 14
- 238000004364 calculation method Methods 0.000 description 13
- 238000009826 distribution Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000005286 illumination Methods 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- 238000011269 treatment regimen Methods 0.000 description 12
- 235000012431 wafers Nutrition 0.000 description 12
- 102000016611 Proteoglycans Human genes 0.000 description 11
- 108010067787 Proteoglycans Proteins 0.000 description 11
- 238000013473 artificial intelligence Methods 0.000 description 11
- 210000004240 ciliary body Anatomy 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 230000004064 dysfunction Effects 0.000 description 11
- 238000009828 non-uniform distribution Methods 0.000 description 11
- 230000002980 postoperative effect Effects 0.000 description 11
- 210000001585 trabecular meshwork Anatomy 0.000 description 11
- 208000010412 Glaucoma Diseases 0.000 description 10
- 238000003491 array Methods 0.000 description 10
- 238000004891 communication Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000010304 firing Methods 0.000 description 10
- 230000010354 integration Effects 0.000 description 10
- 238000002430 laser surgery Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- -1 poly(acrylamide) Polymers 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 230000005855 radiation Effects 0.000 description 10
- 230000008602 contraction Effects 0.000 description 9
- 238000004132 cross linking Methods 0.000 description 9
- 239000007943 implant Substances 0.000 description 9
- 208000002780 macular degeneration Diseases 0.000 description 9
- 230000035790 physiological processes and functions Effects 0.000 description 9
- 230000003595 spectral effect Effects 0.000 description 9
- 238000012876 topography Methods 0.000 description 9
- 230000004304 visual acuity Effects 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000000862 absorption spectrum Methods 0.000 description 8
- 206010064930 age-related macular degeneration Diseases 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000004438 eyesight Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000036571 hydration Effects 0.000 description 8
- 238000006703 hydration reaction Methods 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000003685 thermal hair damage Effects 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 238000000149 argon plasma sintering Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000003831 deregulation Effects 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 230000004424 eye movement Effects 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000541 pulsatile effect Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 6
- 206010049244 Ankyloglossia congenital Diseases 0.000 description 6
- 102000016942 Elastin Human genes 0.000 description 6
- 108010014258 Elastin Proteins 0.000 description 6
- 108010064719 Oxyhemoglobins Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 210000003683 corneal stroma Anatomy 0.000 description 6
- 108010002255 deoxyhemoglobin Proteins 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 229920002549 elastin Polymers 0.000 description 6
- 230000005670 electromagnetic radiation Effects 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004118 muscle contraction Effects 0.000 description 6
- 210000001087 myotubule Anatomy 0.000 description 6
- 238000013439 planning Methods 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 230000004382 visual function Effects 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 239000003889 eye drop Substances 0.000 description 5
- 238000001506 fluorescence spectroscopy Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 208000001491 myopia Diseases 0.000 description 5
- 210000000633 nuclear envelope Anatomy 0.000 description 5
- 210000001328 optic nerve Anatomy 0.000 description 5
- 230000007310 pathophysiology Effects 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 238000004611 spectroscopical analysis Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 241000446313 Lamella Species 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 210000000270 basal cell Anatomy 0.000 description 4
- 210000002555 descemet membrane Anatomy 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000005553 drilling Methods 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 210000001747 pupil Anatomy 0.000 description 4
- 238000001055 reflectance spectroscopy Methods 0.000 description 4
- 208000014733 refractive error Diseases 0.000 description 4
- 230000008844 regulatory mechanism Effects 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000000779 smoke Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 238000004497 NIR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000003287 ciliary artery Anatomy 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002091 elastography Methods 0.000 description 3
- 210000005081 epithelial layer Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 230000004379 myopia Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000004386 ocular blood flow Effects 0.000 description 3
- 235000019645 odor Nutrition 0.000 description 3
- 230000000149 penetrating effect Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012706 support-vector machine Methods 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 208000024304 Choroidal Effusions Diseases 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- 241000208818 Helianthus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010030043 Ocular hypertension Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 201000002154 Pterygium Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000003732 agents acting on the eye Substances 0.000 description 2
- 230000003679 aging effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- DMLAVOWQYNRWNQ-UHFFFAOYSA-N azobenzene Chemical class C1=CC=CC=C1N=NC1=CC=CC=C1 DMLAVOWQYNRWNQ-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 210000002987 choroid plexus Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000012774 diagnostic algorithm Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004980 dosimetry Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 230000005274 electronic transitions Effects 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 238000003709 image segmentation Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 238000000960 laser cooling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000013178 mathematical model Methods 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000012229 microporous material Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000025712 muscle attachment Effects 0.000 description 2
- 239000007783 nanoporous material Substances 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 210000005157 neural retina Anatomy 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 229940023490 ophthalmic product Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001443 photoexcitation Effects 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 230000009894 physiological stress Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009711 regulatory function Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000011268 retreatment Methods 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 2
- 229910010271 silicon carbide Inorganic materials 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000013024 troubleshooting Methods 0.000 description 2
- 230000005641 tunneling Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000003190 viscoelastic substance Substances 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- QNRATNLHPGXHMA-XZHTYLCXSA-N (r)-(6-ethoxyquinolin-4-yl)-[(2s,4s,5r)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)CC)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OCC)C=C21 QNRATNLHPGXHMA-XZHTYLCXSA-N 0.000 description 1
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 1
- 229910000851 Alloy steel Inorganic materials 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010011951 Decompression Sickness Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010012692 Diabetic uveitis Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001065663 Homo sapiens Lipolysis-stimulated lipoprotein receptor Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 208000023715 Ocular surface disease Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- JNDMLEXHDPKVFC-UHFFFAOYSA-N aluminum;oxygen(2-);yttrium(3+) Chemical compound [O-2].[O-2].[O-2].[Al+3].[Y+3] JNDMLEXHDPKVFC-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 210000004155 blood-retinal barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004045 bowman membrane Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000003670 easy-to-clean Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000000301 hemidesmosome Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000006060 molten glass Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000003121 nonmonotonic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000007699 photoisomerization reaction Methods 0.000 description 1
- 239000004038 photonic crystal Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000010255 response to auditory stimulus Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000013349 risk mitigation Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001760 tenon capsule Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000010871 transoral laser microsurgery Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000008154 viscoelastic solution Substances 0.000 description 1
- 229940006076 viscoelastic substance Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 229910019901 yttrium aluminum garnet Inorganic materials 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023117089A JP7696398B2 (ja) | 2017-03-31 | 2023-07-18 | 眼レーザー手術及び治療処置のためのシステム及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480294P | 2017-03-31 | 2017-03-31 | |
| US62/480,294 | 2017-03-31 | ||
| PCT/US2018/025608 WO2018183987A1 (en) | 2017-03-31 | 2018-03-31 | Systems and methods for ocular laser surgery and therapeutic treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117089A Division JP7696398B2 (ja) | 2017-03-31 | 2023-07-18 | 眼レーザー手術及び治療処置のためのシステム及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512917A JP2020512917A (ja) | 2020-04-30 |
| JP2020512917A5 true JP2020512917A5 (enExample) | 2020-07-09 |
Family
ID=63678106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502533A Pending JP2020512917A (ja) | 2017-03-31 | 2018-03-31 | 眼レーザー手術及び治療処置のためのシステム及び方法 |
| JP2023117089A Active JP7696398B2 (ja) | 2017-03-31 | 2023-07-18 | 眼レーザー手術及び治療処置のためのシステム及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117089A Active JP7696398B2 (ja) | 2017-03-31 | 2023-07-18 | 眼レーザー手術及び治療処置のためのシステム及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11026837B2 (enExample) |
| EP (2) | EP4438016A3 (enExample) |
| JP (2) | JP2020512917A (enExample) |
| KR (2) | KR20200024132A (enExample) |
| CN (2) | CN116712252A (enExample) |
| AU (2) | AU2018243837B2 (enExample) |
| CA (1) | CA3058461A1 (enExample) |
| ES (1) | ES2969893T3 (enExample) |
| IL (1) | IL269740B2 (enExample) |
| MX (2) | MX2019011750A (enExample) |
| RU (2) | RU2766775C2 (enExample) |
| SG (1) | SG11201909096WA (enExample) |
| TW (1) | TWI846689B (enExample) |
| WO (1) | WO2018183987A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11771596B2 (en) | 2010-05-10 | 2023-10-03 | Ramot At Tel-Aviv University Ltd. | System and method for treating an eye |
| HUE051987T2 (hu) | 2013-03-15 | 2021-04-28 | Annmarie Hipsley | Rendszerek kötõszövet biomechanikai tulajdonságainak befolyásolására |
| WO2018005891A2 (en) * | 2016-06-29 | 2018-01-04 | Ace Vision Group, Inc. | System and methods using real-time predictive virtual 3d eye finite element modeling for simulation of ocular structure biomechanics |
| US10340046B2 (en) | 2016-10-27 | 2019-07-02 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications |
| US11696952B2 (en) * | 2017-08-17 | 2023-07-11 | Lutronic Vision Inc. | Nanocapsule-based ocular therapy |
| WO2019155344A1 (en) * | 2018-02-09 | 2019-08-15 | Novartis Ag | System inverting controller for laser scanning systems |
| EP3817698A4 (en) | 2018-07-02 | 2022-03-30 | Belkin Laser Ltd. | DIRECT SELECTIVE LASER TRABECULOPLASTY |
| US12295886B2 (en) | 2018-10-28 | 2025-05-13 | Belkin Vision Ltd. | Protection for direct selective laser trabeculoplasty |
| US12416818B2 (en) | 2019-03-01 | 2025-09-16 | Sightglass Vision, Inc. | Ophthalmic lenses for reducing myopic progression and methods of making the same |
| US11389239B2 (en) | 2019-04-19 | 2022-07-19 | Elios Vision, Inc. | Enhanced fiber probes for ELT |
| US11672475B2 (en) | 2019-04-19 | 2023-06-13 | Elios Vision, Inc. | Combination treatment using ELT |
| US11076933B2 (en) | 2019-04-19 | 2021-08-03 | Elt Sight, Inc. | Authentication systems and methods for an excimer laser system |
| US11076992B2 (en) | 2019-04-19 | 2021-08-03 | Elt Sight, Inc. | Methods of transverse placement in ELT |
| US11103382B2 (en) * | 2019-04-19 | 2021-08-31 | Elt Sight, Inc. | Systems and methods for preforming an intraocular procedure for treating an eye condition |
| US11234866B2 (en) | 2019-04-19 | 2022-02-01 | Elios Vision, Inc. | Personalization of excimer laser fibers |
| ES3034085T3 (en) | 2019-04-24 | 2025-08-12 | Progenics Pharm Inc | Systems and methods for automated and interactive analysis of bone scan images for detection of metastases |
| JP2022536000A (ja) * | 2019-05-04 | 2022-08-10 | エース ヴィジョン グループ， インコーポレイテッド | 眼レーザ外科手術および療法的治療のためのシステムおよび方法 |
| US11516388B2 (en) | 2019-06-20 | 2022-11-29 | Cilag Gmbh International | Pulsed illumination in a fluorescence imaging system |
| US11023095B2 (en) * | 2019-07-12 | 2021-06-01 | Cinemoi North America, LLC | Providing a first person view in a virtual world using a lens |
| WO2021048723A1 (en) * | 2019-09-12 | 2021-03-18 | Belkin Laser Ltd. | Selective laser stimulation of corneal stem cells |
| DE102019214020A1 (de) | 2019-09-13 | 2021-03-18 | Carl Zeiss Meditec Ag | Verfahren und Vorrichtung zur Generierung von Steuerdaten für ein ophthalmologisches Lasertherapiegerät |
| US11958183B2 (en) | 2019-09-19 | 2024-04-16 | The Research Foundation For The State University Of New York | Negotiation-based human-robot collaboration via augmented reality |
| US12417533B2 (en) | 2019-09-27 | 2025-09-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| DE102019007147A1 (de) * | 2019-10-09 | 2021-04-15 | Carl Zeiss Meditec Ag | Anordnung zur Laser-Vitreolyse |
| CN110795808A (zh) * | 2019-10-31 | 2020-02-14 | 北京理工大学 | 一种脑环境参数确定装置、方法及电子设备 |
| KR102329313B1 (ko) * | 2019-12-10 | 2021-11-19 | 사회복지법인 삼성생명공익재단 | 전안부 이미지를 이용한 각막 병변 분석 시스템 및 방법 그리고 컴퓨터로 판독 가능한 기록 매체 |
| CN111078210B (zh) * | 2019-12-11 | 2023-06-30 | 中国科学院光电技术研究所 | 一种用于自适应光学操控系统的QT和Matlab多线程混合编程软件架构 |
| JP2023513178A (ja) * | 2020-02-07 | 2023-03-30 | エレックス メディカル プロプライエタリー リミテッド | 直接レーザ線維柱帯形成方法及び装置 |
| CN111427015B (zh) * | 2020-04-02 | 2025-01-28 | 中国人民解放军63892部队 | 基于飞行载体的四源非均匀线阵反向交叉眼干扰方法 |
| GR1010024B (el) * | 2020-05-06 | 2021-06-01 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη |
| FR3112006B1 (fr) * | 2020-06-29 | 2022-07-22 | Unistellar | Procédé et installation pour estimer un paramètre caractéristique de la turbulence atmosphérique |
| JP2023533645A (ja) | 2020-07-19 | 2023-08-04 | ベルキン ヴィジョン リミテッド | 自動嚢切開術 |
| CN111840810B (zh) * | 2020-07-27 | 2022-03-01 | 哈尔滨工业大学 | 一种基于光学相变纳米颗粒的生物组织温度场被动调控方法 |
| JP7595833B2 (ja) * | 2020-09-10 | 2024-12-09 | 株式会社シンクアウト | 白内障手術評価システム |
| RU2750968C1 (ru) * | 2020-10-28 | 2021-07-07 | федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Устройство для определения проекции новообразования глазного дна на склеру |
| TWI774120B (zh) * | 2020-11-10 | 2022-08-11 | 中國醫藥大學 | 生物組織影像分析方法及生物組織影像分析系統 |
| DE102020215583A1 (de) * | 2020-12-09 | 2022-06-09 | Carl Zeiss Meditec Ag | Vorrichtung zur Erzeugung eines gesteigerten Abflusses von Kammerwasser zur Senkung des Augeninnendruckes bei Glaukom |
| CN112656507B (zh) * | 2020-12-31 | 2022-08-26 | 江苏省人民医院（南京医科大学第一附属医院） | 一种构建适用于smile手术切削厚度预测的bp神经网络模型的方法 |
| USD975117S1 (en) * | 2021-01-01 | 2023-01-10 | Lensar, Inc. | Display screen with graphical user interface for a laser-phacoemulsification system |
| US11278452B1 (en) * | 2021-03-24 | 2022-03-22 | Stroma Medical Corporation | Systems and methods for eye imaging and position control |
| DE102021111266B4 (de) * | 2021-04-30 | 2023-06-22 | Schwind Eye-Tech-Solutions Gmbh | Behandlungsvorrichtung und Verfahren zum Bereitstellen von Steuerdaten zur Steuerung eines ophthalmologischen Lasers mit einer raumfüllenden Kurve |
| AR127744A1 (es) * | 2021-10-08 | 2024-02-28 | Cosmo Artificial Intelligence Ai Ltd | Sistemas y métodos implementados por computadora para analizar la calidad del examen de un procedimiento endoscópico |
| TWI778849B (zh) * | 2021-10-29 | 2022-09-21 | 林芸萱 | 光學裝置 |
| CN114343839B (zh) * | 2021-12-30 | 2024-07-23 | 德州环球之光医疗科技股份有限公司 | 一种基于可调的螺旋线型激光光斑的治疗图形转换方法 |
| CN115356844B (zh) * | 2022-07-05 | 2024-09-24 | 电子科技大学 | 一种光谱编码的多模光纤内窥镜成像系统 |
| WO2024011236A1 (en) * | 2022-07-08 | 2024-01-11 | Arcscan, Inc. | Using artificial intelligence to detect and monitor glaucoma |
| US12256153B1 (en) | 2022-08-03 | 2025-03-18 | Meta Platforms Technologies, Llc | Polarization volume hologram combiner enabling wide population coverage, eye tracking accuracy, and glint generation |
| US11918516B1 (en) | 2022-08-30 | 2024-03-05 | Elios Vision, Inc. | Systems and methods for treating patients with closed-angle or narrow-angle glaucoma using an excimer laser unit |
| US12409069B2 (en) | 2022-08-30 | 2025-09-09 | Elios Vision, Inc. | Systems and methods for a combined excimer laser and phacoemulsification unit |
| US11877951B1 (en) | 2022-08-30 | 2024-01-23 | Elios Vision, Inc. | Systems and methods for applying excimer laser energy with transverse placement in the eye |
| US11903876B1 (en) | 2022-08-30 | 2024-02-20 | Elios Vision, Inc. | Systems and methods for prophylactic treatment of an eye using an excimer laser unit |
| CN115406341B (zh) * | 2022-08-30 | 2025-04-15 | 中国核动力研究设计院 | 一种电涡流位移传感器可靠性分析方法及系统 |
| EP4633565A1 (en) * | 2022-12-15 | 2025-10-22 | Belkin Vision Ltd. | Automated transscleral cyclophotocoagulation |
| CN116327097B (zh) * | 2023-03-03 | 2023-12-05 | 上海交通大学医学院附属第九人民医院 | 一种内镜检测肿物大小的测量方法和测量装置 |
| TWI846403B (zh) * | 2023-03-25 | 2024-06-21 | 張朝凱 | 瞳孔大小之量測系統及其量測方法 |
| WO2025169204A1 (en) * | 2024-02-11 | 2025-08-14 | Lumenis Be Ltd. | Eye shields for using in optical treatment systems |
| WO2025177109A1 (en) * | 2024-02-22 | 2025-08-28 | Alcon Inc. | Dynamic surgical feedback for eye tissue |
| WO2025231302A1 (en) * | 2024-05-01 | 2025-11-06 | Horizon Surgical Systems, Inc. | Capsulotomy tool and method |
| EP4652948A1 (en) * | 2024-05-24 | 2025-11-26 | Fotona d.o.o. | Apparatus for treatment of a target area |
| CN119523429B (zh) * | 2025-01-16 | 2025-05-02 | 端粒美(绍兴)激光科技有限公司 | 飞秒激光三维扫描系统、方法、设备及介质 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5415861A (en) | 1991-07-01 | 1995-05-16 | Avon Products, Inc. | Composition and method for visibly reducing the size of skin pores |
| WO2002064031A2 (en) * | 2001-02-09 | 2002-08-22 | Sensomotoric Instruments Gmbh | Multidimensional eye tracking and position measurement system |
| AU2006225120A1 (en) | 2005-03-15 | 2006-09-21 | Annmarie Hipsley | System and method for treating connective tissue |
| US20140163597A1 (en) | 2012-12-10 | 2014-06-12 | Annmarie Hipsley | System and Method for Treating Connective Tissue |
| EP2457546A3 (en) | 2005-04-26 | 2013-02-20 | Biolase, Inc. | Methods for treating eye conditions |
| US10842675B2 (en) * | 2006-01-20 | 2020-11-24 | Lensar, Inc. | System and method for treating the structure of the human lens with a laser |
| US20080058779A1 (en) * | 2006-09-05 | 2008-03-06 | Ace Vision Usa | Method for Affecting Biomechanical Properties of Biological Tissue |
| EP2150169B1 (en) * | 2007-05-17 | 2016-04-06 | AMO Development, LLC | Customized laser epithelial ablation systems |
| US8945103B2 (en) * | 2007-10-30 | 2015-02-03 | Iridex Corporation | Contact probe for the delivery of laser energy |
| US8230866B2 (en) * | 2007-12-13 | 2012-07-31 | Carl Zeiss Meditec Ag | Systems and methods for treating glaucoma and systems and methods for imaging a portion of an eye |
| AU2010275380A1 (en) * | 2009-07-24 | 2012-02-16 | Lensar, Inc. | System and method for performing ladar assisted procedures on the lens of an eye |
| WO2011073796A2 (en) * | 2009-12-16 | 2011-06-23 | Chrontech Pharma Ab | Injection needle and device |
| US9161857B2 (en) * | 2010-07-29 | 2015-10-20 | Eos Holdings, Llc | Presbyopic vision correction with controlled 3-D patterned mechanical weakening of scleral tissue |
| CN105307586B (zh) * | 2013-03-15 | 2018-03-16 | 阿莱耶恩公司 | 巩膜易位弹性调整方法和装置 |
| HUE051987T2 (hu) * | 2013-03-15 | 2021-04-28 | Annmarie Hipsley | Rendszerek kötõszövet biomechanikai tulajdonságainak befolyásolására |
| JP6611613B2 (ja) * | 2013-06-13 | 2019-11-27 | スリーエム イノベイティブ プロパティズ カンパニー | 微多孔性フィルムを含むテープ |
| US9770362B2 (en) * | 2014-12-23 | 2017-09-26 | Novartis Ag | Wavefront correction for ophthalmic surgical lasers |
| WO2018005891A2 (en) | 2016-06-29 | 2018-01-04 | Ace Vision Group, Inc. | System and methods using real-time predictive virtual 3d eye finite element modeling for simulation of ocular structure biomechanics |
| WO2018005888A1 (en) | 2016-06-29 | 2018-01-04 | Ace Vision Group, Inc. | 3-dimensional model creation using whole eye finite element modeling of human ocular structures |
-
2018
- 2018-03-31 US US15/942,513 patent/US11026837B2/en active Active
- 2018-03-31 EP EP23213883.4A patent/EP4438016A3/en active Pending
- 2018-03-31 KR KR1020197032272A patent/KR20200024132A/ko not_active Ceased
- 2018-03-31 CA CA3058461A patent/CA3058461A1/en active Pending
- 2018-03-31 RU RU2019134801A patent/RU2766775C2/ru active
- 2018-03-31 MX MX2019011750A patent/MX2019011750A/es unknown
- 2018-03-31 AU AU2018243837A patent/AU2018243837B2/en active Active
- 2018-03-31 JP JP2020502533A patent/JP2020512917A/ja active Pending
- 2018-03-31 CN CN202310474873.5A patent/CN116712252A/zh active Pending
- 2018-03-31 CN CN201880035809.4A patent/CN110891511B/zh active Active
- 2018-03-31 EP EP18776885.8A patent/EP3600109B1/en active Active
- 2018-03-31 IL IL269740A patent/IL269740B2/en unknown
- 2018-03-31 SG SG11201909096W patent/SG11201909096WA/en unknown
- 2018-03-31 ES ES18776885T patent/ES2969893T3/es active Active
- 2018-03-31 KR KR1020237037443A patent/KR102777976B1/ko active Active
- 2018-03-31 WO PCT/US2018/025608 patent/WO2018183987A1/en not_active Ceased
- 2018-03-31 RU RU2022103876A patent/RU2022103876A/ru unknown
-
2019
- 2019-03-29 TW TW108111355A patent/TWI846689B/zh active
- 2019-09-30 MX MX2023009772A patent/MX2023009772A/es unknown
-
2021
- 2021-05-17 US US17/322,873 patent/US20210338484A1/en not_active Abandoned
-
2023
- 2023-07-18 JP JP2023117089A patent/JP7696398B2/ja active Active
-
2024
- 2024-01-09 AU AU2024200128A patent/AU2024200128A1/en active Pending
-
2025
- 2025-01-30 US US19/041,801 patent/US20250318954A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7696398B2 (ja) | 眼レーザー手術及び治療処置のためのシステム及び方法 | |
| JP2020512917A5 (enExample) | ||
| TWI865533B (zh) | 用於眼部雷射手術及治療處理的系統及方法 | |
| US10258506B2 (en) | Laser therapy system for noninvasive correction of the refractive system of the eye | |
| US20140171926A1 (en) | Laser therapy system and method for treatment of a collagen structure and of varicose blood vessels in an eye | |
| RU2816797C2 (ru) | Система для проведения лечения биологической ткани глаза путем микропорации | |
| HK40016651A (en) | Systems and methods for ocular laser surgery and therapeutic treatments | |
| HK40016651B (en) | Systems and methods for ocular laser surgery and therapeutic treatments | |
| BR112019020532B1 (pt) | Sistema para oferecer tratamentos médicos de microporação para melhorar a biomecânica | |
| HK40062577A (en) | Systems and methods for ocular laser surgery and therapeutic treatments |